PTC and Lilly Just Bought Sangamo for Parts: What the $163.55M Bankruptcy Auction Says About Gene Therapy in 2026

Last updated: August 14, 2026

In an August 13 bankruptcy auction, PTC Therapeutics agreed to pay up to $211 million for Sangamo’s Fabry disease gene therapy while Eli Lilly paid $50 million for its delivery and genome editing platforms. Total cash at closing: $163.55 million.

This page covers the full auction results, the assets each buyer takes, the road to a Fabry approval, what remains for sale, and the rest of Thursday’s news: the Zenbexus approval in multiple myeloma, zipalertinib’s Phase 3 win in lung cancer, Zealand’s $100 million royalty sale, and Lilly’s retatrutide lawsuits.

Who bought Sangamo’s assets in the bankruptcy auction, and for how much?

Two buyers took the core assets. PTC Therapeutics won the Fabry disease gene therapy for $111 million in cash plus up to $100 million in approval milestones. Eli Lilly and Company paid $50 million in cash for Sangamo’s technology platforms and its preclinical prion disease program.

Sangamo Therapeutics announced the results of its court supervised auction on August 13, 2026. The company has been operating under Chapter 11 protection in the US Bankruptcy Court for the District of Delaware (case 26-10989), and the sale ran as a Section 363 asset auction.

That comes to $163.55 million in cash at closing plus up to $100 million in contingent payments, with sale hearings expected in the third quarter of 2026. Endpoints News summarized the total potential consideration as roughly $264 million.

What did PTC Therapeutics get for up to $211 million?

PTC gets isaralgagene civaparvovec, also called ST-920, a one time intravenous gene therapy for Fabry disease that delivers a working copy of the GLA gene so patients produce their own alpha galactosidase A enzyme. Sangamo had already begun a rolling submission to the FDA seeking accelerated approval.

Fabry disease is a rare lysosomal storage disorder in which deficient alpha galactosidase A activity lets a fatty substrate accumulate in blood vessels, kidneys, heart, and nerves. Today’s standard of care is lifelong enzyme replacement infusions or oral chaperone therapy, a market BioPharma Dive puts at more than $2 billion a year. A durable one time therapy is the category’s long promised alternative.

The milestone structure tells you how the deal is priced: $80 million of the $100 million contingent piece pays only on accelerated approval, with $20 million reserved for full approval on longer follow up. Reporting from BioPharma Dive indicates PTC plans to complete the biologics license application in the fourth quarter of 2026, with a potential launch in 2027 if the FDA cooperates. Analysts were constructive on the price: Leerink Partners called the deal initially favorable, Jefferies called it low risk with strong upside, and RBC Capital Markets noted gene therapy remains somewhat out of favor, which is exactly why the asset was available at this price.

What did Eli Lilly get for $50 million?

Lilly bought the machinery rather than a medicine. The $50 million covers Sangamo’s engineered capsid delivery platform, its zinc finger genome editing platform, the MINT modular integrase platform, and ST-506, a preclinical epigenetic regulation program for prion disease.

The capsid technology is the strategic piece. Getting genetic medicines across the blood brain barrier is the binding constraint on the entire neurology gene therapy field, and Sangamo’s engineered capsids were the asset large partners kept licensing even as the company itself ran out of money. Lilly, which has been building a genetic medicines effort around exactly this delivery problem, now owns the platform outright, with no milestones and no royalties owed. The transaction is expected to close September 4, 2026.

Why did a gene editing pioneer end up in Chapter 11?

Sangamo spent almost three decades pioneering zinc finger genome editing, and its collapse traces to a pattern: large partners funded its most ambitious programs, then handed them back. BioPharma Dive describes a series of missteps, research setbacks, and ill fated partnerships, including Sanofi walking away from their sickle cell collaboration.

Each returned program left Sangamo carrying development costs it could not fund alone. The company kept generating scientifically credible assets, including the Fabry program now heading to PTC and the capsids now heading to Lilly, but never converted them into a durable balance sheet before the capital markets closed to it. The bankruptcy did not extinguish the science. It repriced it, and the auction shows precisely who was willing to pay for which piece.

What Sangamo assets are still for sale?

Three groups of assets remain on the block. Sangamo says it continues to solicit offers for ST-503, an epigenetic regulation program for chronic neuropathic pain; giroctocogene fitelparvovec, the Phase 3 hemophilia A gene therapy previously partnered with Pfizer; and its cell therapy and regulatory T cell assets.

Giroctocogene fitelparvovec is the notable orphan here: a late stage asset in a disease where gene therapy is already a commercial category, still without a buyer. Whether it finds one, and at what price, will be a useful second data point on how buyers value clinical stage gene therapy versus platforms.

What does the auction say about how the market prices gene therapy in 2026?

The auction split one company into its two kinds of value and priced them separately. The platforms, which generate no clinical risk and feed everyone’s pipelines, drew a large pharma paying cash with no contingencies. The lead drug, which is filed and close to market, drew a specialist paying about half its consideration only if regulators say yes.

That is the cleanest possible expression of a theme we have tracked all week: infrastructure captures value with less binary risk than drug development. The buyers of picks and shovels pay firm prices; the buyers of molecules structure their downside. It also echoes the pattern in the $8 billion radiodiagnostics bid that opened the week and in the manufacturing driven FDA rejections we covered Wednesday: control of the enabling layer, whether a capsid, a fill finish line, or an imaging agent, is what the market pays for with confidence.

What did the FDA approve in multiple myeloma this week?

On August 13 the FDA granted accelerated approval to Bristol Myers Squibb’s Zenbexus (iberdomide), the first CELMoD agent, in combination with daratumumab and hyaluronidase-fihj plus dexamethasone, for adults with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.

The approval covers patients as early as first relapse and rests on the Phase 3 EXCALIBER-RRMM trial, which randomized 939 patients. In the primary efficacy analysis of 420 patients, the Zenbexus regimen produced a minimal residual disease negative complete response in 41 percent of patients versus 21 percent for the daratumumab, bortezomib, and dexamethasone comparator (p<0.0001) at a median follow up of 16 months. Continued approval is contingent on confirmatory evidence.

Iberdomide is the molecule Bristol Myers designed to succeed lenalidomide, the multibillion dollar immunomodulatory franchise that has been eroding to generics. The regulatory notable is the endpoint: this is a major approval built on MRD negativity, the surrogate the FDA has accepted as a basis for accelerated approval in myeloma, and it converts that policy into a franchise scale commercial fact.

How did zipalertinib change the EGFR exon 20 lung cancer race?

Zipalertinib plus platinum chemotherapy met its primary endpoint of progression free survival at a planned interim analysis of the Phase 3 REZILIENT3 trial in previously untreated EGFR exon 20 insertion non small cell lung cancer, Taiho and Cullinan Therapeutics announced. The 285 patient trial compared the combination against chemotherapy alone.

The companies called the improvement statistically significant and clinically meaningful, said safety was manageable, and will discuss a first line submission with the FDA, with full data going to a coming medical congress. The economics matter for Cullinan: per the company’s SEC filings, Taiho owes it $100 million on a first line US approval and $30 million on a second line approval, and the partners split US pretax profits evenly. A second line application is already pending with an FDA decision due February 27, 2027, per Fierce Biotech, which also notes the incumbent it is chasing: Johnson & Johnson’s Rybrevant, approved in this population since 2021 in later lines and 2024 in first line, with combined Rybrevant and Lazcluze sales of $546 million in the first half of 2026 by Fierce’s accounting.

Why did Zealand Pharma sell its rusfertide royalty for $100 million?

Zealand Pharma disclosed in its first half report that it has monetized its royalty interest in rusfertide through a $100 million royalty purchase agreement with Royalty Pharma, announced August 12. Rusfertide is the Takeda and Protagonist hepcidin mimetic for polycythemia vera whose FDA decision is expected this quarter.

The timing is the story: Zealand converted a contingent stream tied to a binary regulatory event into cash before the event, and Royalty Pharma, the capital infrastructure of the industry, took the other side. Zealand itself heads into its amylin era well funded, reporting DKK 14.5 billion in cash and its lead obesity asset petrelintide now in Phase 3.

What is Lilly doing about the retatrutide black market?

Eli Lilly filed six lawsuits against US companies selling black market retatrutide, its triple agonist obesity drug candidate, naming Aesthetic Envy Cosmetic Centers, Astra Peptides, Legendary Peptides, Striker Pharmacy, Texas Peptides, and Lone Star Peptide Co. The suits target compounders, med spas, and online sellers marketing the unapproved molecule as research grade material.

Lilly says it has referred more than 200 individuals and entities to regulators and reported more than 14,000 websites and listings across over 100 countries, and it is publicly calling on platforms, credit card companies, and payment processors to cut the market off. Retatrutide is in Phase 3 and approved nowhere in the world, with a regulatory filing expected in the first quarter of 2027. A company suing to protect a medicine it cannot yet sell is defending launch economics in advance, and it is also a live demonstration of how much demand is waiting for the drug.

Frequently asked questions

What is isaralgagene civaparvovec (ST-920)?

Isaralgagene civaparvovec, or ST-920, is an investigational one time gene therapy for Fabry disease. Delivered by intravenous infusion, it carries a functional copy of the GLA gene so the patient’s own liver produces alpha galactosidase A, the enzyme deficient in Fabry disease.

Is ST-920 approved by the FDA?

No. Sangamo began a rolling biologics license application seeking accelerated approval, and PTC Therapeutics, its new owner, plans to complete the submission in the fourth quarter of 2026, per BioPharma Dive. Any approval decision would come after the FDA reviews the completed file.

When could PTC’s Fabry gene therapy reach patients?

If the BLA is completed in late 2026 and the FDA grants accelerated approval, a launch could come in 2027, per BioPharma Dive reporting. The deal’s milestone structure pays Sangamo’s estate $80 million on accelerated approval and $20 million on full approval.

What is Fabry disease?

Fabry disease is a rare inherited lysosomal storage disorder. Mutations in the GLA gene reduce alpha galactosidase A enzyme activity, allowing a fatty substrate called Gb3 to build up in blood vessels, kidneys, heart, and nervous system, which drives pain, kidney failure, and cardiovascular disease.

What exactly did Eli Lilly buy from Sangamo?

Lilly paid $50 million in cash for Sangamo’s engineered capsid delivery platform, its zinc finger genome editing platform, its MINT modular integrase platform, and ST-506, a preclinical epigenetic program for prion disease. The purchase carries no milestones and is expected to close September 4, 2026.

Why did Sangamo Therapeutics file for bankruptcy?

Sangamo filed for Chapter 11 after years of setbacks in which large partners, including Sanofi in sickle cell disease, returned programs the company could not fund alone. Despite scientifically credible assets, it ran out of capital before converting them into durable revenue.

What Sangamo programs are still unsold?

Sangamo’s estate is still marketing ST-503 for chronic neuropathic pain, giroctocogene fitelparvovec, its Phase 3 hemophilia A gene therapy, and its cell therapy and regulatory T cell assets. Offers are being solicited under the same court supervised process.

What is Zenbexus (iberdomide)?

Zenbexus is Bristol Myers Squibb’s brand name for iberdomide, the first approved CELMoD agent. CELMoDs are oral molecules that direct the cell’s protein disposal machinery to degrade the transcription factors Ikaros and Aiolos, the mechanism family that made lenalidomide work, engineered for deeper effect.

What data supported the Zenbexus approval?

The Phase 3 EXCALIBER-RRMM trial, which randomized 939 relapsed or refractory multiple myeloma patients. In the primary analysis, 41 percent of patients on the Zenbexus regimen achieved a minimal residual disease negative complete response versus 21 percent on the comparator regimen, at 16 months median follow up.

What does MRD negative complete response mean?

Minimal residual disease negativity means no detectable cancer cells at a sensitivity of about one cell in a hundred thousand or better, on top of a conventional complete response. The FDA accepts it as an early surrogate endpoint supporting accelerated approval in multiple myeloma.

What is zipalertinib and who is developing it?

Zipalertinib (CLN-081/TAS6417) is an oral EGFR tyrosine kinase inhibitor designed for exon 20 insertion mutations, developed by Taiho Oncology and Taiho Pharmaceutical with Cullinan Therapeutics. It just met its progression free survival endpoint in the first line Phase 3 REZILIENT3 trial.

When will the FDA decide on zipalertinib?

A second line application is under FDA review with a decision due by February 27, 2027, per Fierce Biotech. The companies plan to discuss a first line submission with the FDA based on the REZILIENT3 interim results announced this week.

What is rusfertide and when is its FDA decision?

Rusfertide is a hepcidin mimetic peptide for polycythemia vera developed by Protagonist Therapeutics and partnered with Takeda. It met all endpoints in the Phase 3 VERIFY trial, and its FDA decision under priority review is expected in the third quarter of 2026.

Is retatrutide approved anywhere in the world?

No. Retatrutide, Eli Lilly’s triple hormone receptor agonist for obesity, remains investigational in Phase 3 trials and has not been approved by any regulator. Lilly expects to file for approval in the first quarter of 2027. Products sold today as retatrutide are unapproved and unverified.

Why is Eli Lilly suing peptide sellers?

Lilly filed six lawsuits against US compounders, med spas, and online sellers marketing black market retatrutide, arguing they are illegal drug distributors selling an unapproved molecule. The company has also referred over 200 sellers to regulators and reported more than 14,000 listings worldwide.

Sources

Primary sources

• Sangamo Therapeutics press release, August 13, 2026: auction results, buyer and price detail, court and case information, closing timelines.
• Bristol Myers Squibb press release, August 13, 2026: Zenbexus accelerated approval, EXCALIBER-RRMM efficacy and safety data.
• Taiho Oncology and Cullinan Therapeutics press release, August 12, 2026: REZILIENT3 interim analysis result and regulatory plans.
• Cullinan Therapeutics SEC filings: Taiho milestone and US profit share terms.
• Zealand Pharma first half 2026 report, August 13, 2026: Royalty Pharma rusfertide royalty purchase agreement, cash position, petrelintide status.
• Eli Lilly press release, August 12, 2026: retatrutide lawsuits, referral and takedown figures.
• Ovid Therapeutics second quarter 2026 report, August 13, 2026: soticlestat NewCo terms.

Trade press

• Endpoints News, August 13, 2026: Sangamo auction coverage, Tavneos EMA documentation, PDUFA VIII commitments.
• BioPharma Dive, August 13, 2026: PTC Fabry deal analysis, Sangamo history, analyst commentary, Fabry market size.
• Fierce Biotech, August 13, 2026: zipalertinib deal economics and EGFR exon 20 competitive context.
• MedTech Dive, August 12, 2026: Abbott and Google glucose data and AI coaching partnership.

Related coverage

• Definium’s LSD pill beat placebo by 5.4 points in Phase 3 anxiety: what the Voyage data mean for GAD treatment in 2026
• Why the FDA rejected ITM’s radiopharma therapy and stalled Scholar Rock’s SMA filing in August 2026
• Replimune’s Tudriqev approval and the $8 billion radiopharma infrastructure bid
• Sionna’s cystic fibrosis trial failure: what happened and what it means for Vertex and CF patients in 2026